JPMorgan: Buy AbbVie, Low Valuation Belies EPS Growth Potential

AbbVie (ABBV) is rising Wednesday, helped in part by a bullish note from JPMorgan. Analyst Chris Schott and his team resumed coverage of the pharma giant with an Overweight rating and $75 price target. They write that the Pharmacyclics acquisition as a good move, as it adds a “solid growth platform” to AbbVie’s portfolio, They [...]